Julie Wolf - Concepedia

Author

Julie Wolf

Momenta Pharmaceuticals (United States)

Also Known As

Julie L. Wolf, Julie Wolf

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Momenta Pharmaceuticals (United States)Massachusetts General Hospital La Roche College Memorial Sloan Kettering Cancer Center Micro Focus (United States)

About

Julie Wolf is an author at Momenta Pharmaceuticals (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	352
2	Engineering	1	1	45
3	Health Sciences	1	1	54
4	Public Health	1	1	17
5	Social Sciences	1	1	37

Julie Wolf

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Effects of Smoking on the Pharmacokinetics of Erlotinib Marta Hamilton, Julie Wolf, Jason Rusk, Clinical Cancer Research	2006	308
Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys Daniel W. Drolet, J. Arly Nelson, Christopher E. Tucker, Pharmaceutical Research	2000	202
Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers Andrew Hughes, Mary O’Brien, W. Jeffrey Petty, Journal of Clinical Oncology	2009	142
Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects Paul Frohna, Jianfeng Lu, Steve Eppler, The Journal of Clinical Pharmacology Oral BioavailabilityHealthy SubjectsPharmacological StudyMedicineReceptor Tyrosine Kinase	2006	109
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Frank C. Richardson, Geoffrey D. Young, Regina Sennello, PubMed Cancer ManagementPathologyCancer BiologyVimentin Protein ExpressionPlacebo Patients	2012	54
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial Tomislav Dragovich, Mark S. Huberman, Daniel D. Von Hoff, Cancer Chemotherapy and Pharmacology Pancreatic CancerGastrointestinal OncologyMedicinePharmacologyPhase Ib Trial	2006	49
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects Marta Hamilton, Julie Wolf, Daniel W. Drolet, Cancer Chemotherapy and Pharmacology Healthy SubjectsErlotinib PharmacokineticsPharmacological StudyMedicinePrototypical Cyp3a4 Inducer	2014	46
Microbial Reducibility of Fe(III) Phases Associated with the Genesis of Iron Ore Caves in the Iron Quadrangle, Minas Gerais, Brazil Ceth W. Parker, Julie Wolf, Augusto S. Auler, Minerals Iron OreIron Ore CavesEngineeringIron MetabolismMicrobial Reducibility	2013	45
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results Eileen M. O’Reilly, James Roach, Paul Miller, The Oncologist	2017	44
Seasonal alteration in taste detection and recognition threshold in seasonal affective disorder: the proximate source of carbohydrate craving Paul A. Arbisi, Allen S. Levine, Jill Nerenberg, Psychiatry Research NeuropsychologyPsychiatryBehavioral NeuroscienceAffective NeurosciencePsychology	1996	37

Page 1